Table 1.
The patients’ characteristics and demographic data
| Characteristic | No. (%) (n=36) |
|---|---|
| Age, median (range, yr) | 60 (39–81) |
| Sex | |
| Male | 17 (47.2) |
| Female | 19 (52.8) |
| Smoking status | |
| Non-smokers | 27 (75.0) |
| Former or current-smokers | 9 (25.0) |
| ECOG PS | |
| 0 | 6 (16.7) |
| 1 | 30 (83.3) |
| Stage | |
| Postoperation recurrence | 5 (13.9) |
| 4A | 5 (13.9) |
| 4B | 26 (72.2) |
| Brain metastasis at baseline | |
| Yes | 22 (61.1) |
| No | 14 (38.9) |
| Baseline EGFR mutation status | |
| Exon 19 deletion | 14 (38.9) |
| Exon 21 L858R point mutation | 22 (61.1) |
| First-line EGFR-TKI | |
| Gefitinib | 3 (8.3) |
| Erlotinib | 17 (47.2) |
| Afatinib | 16 (44.5) |
| Treatment response | |
| Stable disease | 6 (16.7) |
| Partial response | 28 (77.7) |
| Could not be evaluated | 2 (5.6) |
| Objective response rate (%) | 77.8 |
| Disease control rate (%) | 94.4 |
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.